NASHUA, N.H., April 20 /PRNewswire-FirstCall/ -- iCAD(R), Inc. , provider of Computer Aided Detection (CAD) solutions with industry leading detection in subtle forms of breast cancer, announced the arbitration decision on Case No. 13133Y00865 “R2 Technology and Shih-Ping Wang vs. iCAD.” In this case, brought by R2, iCAD’s competitor alleged that iCAD infringed two R2 patents. A panel of three experienced arbitrators rejected all of R2’s claims, finding that iCAD did not infringe any patent asserted by R2.
“This is a tremendous win not just for iCAD,” stated W. Scott Parr, iCAD’s President & CEO, “but for the premise that computer aided detection should be affordable and accessible to all women at risk of breast cancer.”
In response to the arbitration commenced by R2, iCAD asserted in a counterclaim that R2 infringed several iCAD patents. The arbitrators found that R2 did not infringe on those patents.
Parr concluded, “We have been deeply impressed by the arbitration panel’s litigation experience and patent expertise, their candor, courtesy and thoroughness in handling the proceedings. We are very pleased at the outcome.”
About iCAD, Inc.
iCAD, Inc. is an industry-leading provider of Computer-Aided Detection (CAD) solutions that enable healthcare professionals to identify cancer and other life-threatening conditions earlier by making medical services more effective, more accessible and more affordable for patients worldwide. Recipient of Frost & Sullivan’s Growth Strategy Leadership award, iCAD offers a comprehensive range of high-performance, upgradeable CAD systems for the high, mid and low volume mammography markets. As the most frequently selected CAD solution for film-based and digital breast screening, iCAD is entrusted with the task of early cancer detection by over eleven hundred women’s healthcare centers worldwide. For more information, call +1 877 iCADnow or visit http://www.icadmed.com .
“Safe Harbor” Statement under the Private Securities Litigation Reform Act of 1995:
Certain statements contained in this News Release constitute “forward- looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995. Such forward-looking statements involve a number of known and unknown risks, uncertainties and other factors which may cause the actual results, performance or achievements of the Company to be materially different from any future results, performance or achievements expressed or implied by such forward-looking statements. Such factors include, but are not limited to, the risks of uncertainty of patent protection, the impact of supply and manufacturing constraints or difficulties, product market acceptance, possible technological obsolescence, increased competition, customer concentration and other risks detailed in the Company’s filings with the Securities and Exchange Commission. The words “believe,” “demonstrate,” “intend,” “expect,” “estimate,” “anticipate,” “likely,” and similar expressions identify forward-looking statements. Readers are cautioned not to place undue reliance on those forward-looking statements, which speak only as of the date the statement was made. The Company is under no obligation to provide any updates to any information contained in this release.
iCAD and SecondLook are registered trademarks of iCAD, Inc.
iCAD, Inc.
CONTACT: Kevin McGrath, of Cameron Associates, +1-212-245-4577,kevin@cameronassoc.com, for iCAD, Inc.
Web site: http://www.icadmed.com/
